| Title: |
Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea |
| Authors: |
Shim, JS; Jin, J; Kim, SH; Lee, T; Jang, AS; Park, CS; Jung, JW; Kwon, JW; Moon, JY; Yang, MS; Lee, J; Choi, JH; Shin, YS; Kim, HK; Kim, S; Kim, JH; Cho, SH; Nam, YH; Park, SY; Hur, GY; Park, HK; Jin, HJ; Lee, JH; Park, JW; Yoon, HJ; Choi, BW; Cho, YJ; Kim, MH; Kim, TB; Cohort for Reality and Evolution of Adult Asthma in Korea (COREA) Study Group |
| Contributors: |
103243; Shin, YS |
| Publication Year: |
2022 |
| Subject Terms: |
Asthma; Muscarinic antagonists; Predictor; Tiotropium; Treatment response |
| Description: |
BACKGROUND: Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma. However, real-world studies on the predictors of response to tiotropium are limited. We investigated the real-world use of tiotropium in asthmatic adult patients in Korea and we identified predictors of positive response to tiotropium add-on. METHODS: We performed a multicenter, retrospective, cohort study using data from the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA). We enrolled asthmatic participants who took ICS-LABA with at least 2 consecutive lung function tests at 3-month intervals. We compared tiotropium users and non-users, as well as tiotropium responders and non-responders to predict positive responses to tiotropium, defined as 1) increase in forced expiratory volume in 1 s (FEV1) >/= 10% or 100 mL; and 2) increase in asthma control test (ACT) score >/=3 after 3 months of treatment. RESULTS: The study included 413 tiotropium users and 1756 tiotropium non-users. Tiotropium users had low baseline lung function and high exacerbation rate, suggesting more severe asthma. Clinical predictors for positive response to tiotropium add-on were 1) positive bronchodilator response (BDR) [odds ratio (OR) = 6.8, 95% confidence interval (CI): 1.6-47.4, P = 0.021] for FEV1 responders; 2) doctor-diagnosed asthma-chronic obstructive pulmonary disease overlap (ACO) [OR = 12.6, 95% CI: 1.8-161.5, P = 0.024], and 3) initial ACT score |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
J019394551; http://repository.ajou.ac.kr/handle/201003/24601; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679363 |
| DOI: |
10.1016/j.waojou.2022.100720 |
| Availability: |
http://repository.ajou.ac.kr/handle/201003/24601; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679363; https://doi.org/10.1016/j.waojou.2022.100720 |
| Accession Number: |
edsbas.33E4B587 |
| Database: |
BASE |